AU2021232614A1 - Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells - Google Patents

Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells Download PDF

Info

Publication number
AU2021232614A1
AU2021232614A1 AU2021232614A AU2021232614A AU2021232614A1 AU 2021232614 A1 AU2021232614 A1 AU 2021232614A1 AU 2021232614 A AU2021232614 A AU 2021232614A AU 2021232614 A AU2021232614 A AU 2021232614A AU 2021232614 A1 AU2021232614 A1 AU 2021232614A1
Authority
AU
Australia
Prior art keywords
cells
subject
stem cells
mlpscs
mesenchymal lineage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021232614A
Other languages
English (en)
Inventor
Silviu Itescu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900685A external-priority patent/AU2020900685A0/en
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of AU2021232614A1 publication Critical patent/AU2021232614A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2021232614A 2020-03-05 2021-03-04 Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells Pending AU2021232614A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020900685 2020-03-05
AU2020900685A AU2020900685A0 (en) 2020-03-05 Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
PCT/EP2021/055483 WO2021176001A1 (en) 2020-03-05 2021-03-04 Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells

Publications (1)

Publication Number Publication Date
AU2021232614A1 true AU2021232614A1 (en) 2022-09-29

Family

ID=74867509

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021232614A Pending AU2021232614A1 (en) 2020-03-05 2021-03-04 Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells

Country Status (9)

Country Link
US (1) US20230293589A1 (https=)
EP (1) EP4114418A1 (https=)
JP (1) JP2023517035A (https=)
KR (1) KR20220150919A (https=)
CN (1) CN115361958A (https=)
AU (1) AU2021232614A1 (https=)
BR (1) BR112022017557A2 (https=)
CA (1) CA3170255A1 (https=)
WO (1) WO2021176001A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
EP4181935A1 (en) * 2020-07-20 2023-05-24 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
EP3461884B1 (en) * 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
WO2015016761A2 (en) * 2013-08-01 2015-02-05 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
CN105796598A (zh) * 2014-12-29 2016-07-27 西比曼生物科技（上海）有限公司 一种用于治疗慢性阻塞性肺疾病的脂肪间充质祖细胞复合物
US20200108099A1 (en) * 2017-02-15 2020-04-09 Rohto Pharmaceutical Co., Ltd. Therapeutic agent for pulmonary fibrosis, ptprr expression-promotor, and kit for treatment of pulmonary fibrosis
CL2017002357A1 (es) * 2017-09-16 2018-04-20 Cells For Cells S A Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos
CN111297899A (zh) * 2020-02-21 2020-06-19 云南雅盛医疗科技有限公司 一种脐带间充质干细胞在制备治疗新型冠状肺炎药物中的应用

Also Published As

Publication number Publication date
US20230293589A1 (en) 2023-09-21
WO2021176001A1 (en) 2021-09-10
BR112022017557A2 (pt) 2022-12-27
JP2023517035A (ja) 2023-04-21
EP4114418A1 (en) 2023-01-11
CA3170255A1 (en) 2021-09-10
CN115361958A (zh) 2022-11-18
KR20220150919A (ko) 2022-11-11

Similar Documents

Publication Publication Date Title
US20230165904A1 (en) Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
US20230104108A1 (en) Method for treating inflammatory bowel disease ii
US20230097931A1 (en) Method for treating chronic graft versus host disease
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20230172991A1 (en) Method for treating inflammatory bowel disease i
US20240207323A1 (en) Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells
WO2023119239A1 (en) Method of treating severe graft versus host disease
CN117337184A (zh) 使用间充质谱系前体细胞或干细胞治疗急性呼吸窘迫综合征(ards)的方法